Loading...

We've got a brand new version of Simply Wall St! Try it out

Vectus Biosystems

ASX:VBS
Snowflake Description

Weak fundamentals or lack of information.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
VBS
ASX
A$13M
Market Cap
  1. Home
  2. AU
  3. Pharmaceuticals & Biotech
Company description

Vectus Biosystems Limited engages in the medical research and development activities in Australia. The last earnings update was 49 days ago. More info.


Add to Portfolio Compare Print
  • Vectus Biosystems has significant price volatility in the past 3 months.
VBS Share Price and Events
7 Day Returns
-9.4%
ASX:VBS
4.7%
AU Biotechs
0.9%
AU Market
1 Year Returns
-20%
ASX:VBS
50.9%
AU Biotechs
16.3%
AU Market
VBS Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Vectus Biosystems (VBS) -9.4% -33.3% -11.1% -20% -69.6% -
AU Biotechs 4.7% 8.7% 20% 50.9% 168.8% 226.4%
AU Market 0.9% 1.9% 5.1% 16.3% 22.3% 22.5%
1 Year Return vs Industry and Market
  • VBS underperformed the Biotechs industry which returned 50.9% over the past year.
  • VBS underperformed the Market in Australia which returned 16.3% over the past year.
Price Volatility
VBS
Industry
5yr Volatility vs Market

Value

 Is Vectus Biosystems undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Vectus Biosystems is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Vectus Biosystems has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Vectus Biosystems. This is due to cash flow or dividend data being unavailable. The share price is A$0.48.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Vectus Biosystems's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Vectus Biosystems's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:VBS PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in AUD A$-0.07
ASX:VBS Share Price ** ASX (2019-11-17) in AUD A$0.48
Global Biotechs Industry PE Ratio Median Figure of 145 Publicly-Listed Biotechs Companies 30.8x
Australia Market PE Ratio Median Figure of 519 Publicly-Listed Companies 18.63x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Vectus Biosystems.

ASX:VBS PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:VBS Share Price ÷ EPS (both in AUD)

= 0.48 ÷ -0.07

-7.03x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Vectus Biosystems is loss making, we can't compare its value to the Global Biotechs industry average.
  • Vectus Biosystems is loss making, we can't compare the value of its earnings to the Australia market.
Price based on expected Growth
Does Vectus Biosystems's expected growth come at a high price?
Raw Data
ASX:VBS PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -7.03x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Global Biotechs Industry PEG Ratio Median Figure of 85 Publicly-Listed Biotechs Companies 1.39x
Australia Market PEG Ratio Median Figure of 347 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Vectus Biosystems, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Vectus Biosystems's assets?
Raw Data
ASX:VBS PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in AUD A$-0.16
ASX:VBS Share Price * ASX (2019-11-17) in AUD A$0.48
Australia Biotechs Industry PB Ratio Median Figure of 38 Publicly-Listed Biotechs Companies 3.17x
Australia Market PB Ratio Median Figure of 1,584 Publicly-Listed Companies 1.75x
ASX:VBS PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:VBS Share Price ÷ Book Value per Share (both in AUD)

= 0.48 ÷ -0.16

-3.01x

* Primary Listing of Vectus Biosystems.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Vectus Biosystems has negative assets, we can't compare the value of its assets to the AU Biotechs industry average.

Next steps:

  1. Take a look at our analysis of VBS’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Vectus Biosystems's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Biotechs industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Vectus Biosystems's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Vectus Biosystems has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Vectus Biosystems expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Vectus Biosystems has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
13%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Vectus Biosystems expected to grow at an attractive rate?
  • Unable to compare Vectus Biosystems's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Vectus Biosystems's earnings growth to the Australia market average as no estimate data is available.
  • Unable to compare Vectus Biosystems's revenue growth to the Australia market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
ASX:VBS Future Growth Rates Data Sources
Data Point Source Value (per year)
Australia Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 13%
Australia Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 10.3%
Australia Market Earnings Growth Rate Market Cap Weighted Average 9.7%
Australia Market Revenue Growth Rate Market Cap Weighted Average 3.7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:VBS Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:VBS Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2019-06-30 0 -1 -2
2019-03-31 0 -2 -2
2018-12-31 0 -2 -2
2018-09-30 0 -2 -2
2018-06-30 0 -1 -3
2018-03-31 0 -1 -3
2017-12-31 0 -1 -3
2017-09-30 0 -3 -3
2017-06-30 0 -4 -4
2017-03-31 0 -4 -4
2016-12-31 0 -4 -4
2016-09-30 0 -3 -4

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Vectus Biosystems is high growth as no earnings estimate data is available.
  • Unable to determine if Vectus Biosystems is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:VBS Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Vectus Biosystems Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:VBS Past Financials Data
Date (Data in AUD Millions) EPS *
2019-06-30 -0.07
2019-03-31 -0.08
2018-12-31 -0.10
2018-09-30 -0.10
2018-06-30 -0.11
2018-03-31 -0.12
2017-12-31 -0.13
2017-09-30 -0.15
2017-06-30 -0.16
2017-03-31 -0.17
2016-12-31 -0.18
2016-09-30 -0.17

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Vectus Biosystems will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of VBS’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Vectus Biosystems's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Vectus Biosystems's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Vectus Biosystems's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Vectus Biosystems has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Vectus Biosystems performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Vectus Biosystems's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Vectus Biosystems does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Vectus Biosystems's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Vectus Biosystems's 1-year growth to the Global Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Vectus Biosystems's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Vectus Biosystems Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:VBS Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 0.00 -1.60 1.64 0.71
2019-03-31 0.00 -1.91 1.92 0.76
2018-12-31 0.00 -2.22 2.21 0.81
2018-09-30 0.00 -2.40 2.29 1.21
2018-06-30 0.00 -2.59 2.37 1.60
2018-03-31 0.01 -2.85 2.44 1.81
2017-12-31 0.02 -3.12 2.51 2.02
2017-09-30 0.03 -3.46 2.55 2.14
2017-06-30 0.05 -3.79 2.58 2.26
2017-03-31 0.07 -3.83 2.57 2.29
2016-12-31 0.09 -3.86 2.56 2.32
2016-09-30 0.08 -3.54 2.44 1.90
2016-06-30 0.08 -3.21 2.32 1.48
2015-06-30 0.00 -1.66 1.47 0.76
2014-06-30 0.87 -1.48 0.96
2013-06-30 0.66 -1.24 0.86

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Vectus Biosystems has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Vectus Biosystems has efficiently used its assets last year compared to the Global Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Vectus Biosystems improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
X
Past performance checks
We assess Vectus Biosystems's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Vectus Biosystems has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Vectus Biosystems's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Vectus Biosystems's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Vectus Biosystems's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Vectus Biosystems's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Vectus Biosystems's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Vectus Biosystems has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Vectus Biosystems Company Filings, last reported 4 months ago.

ASX:VBS Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 -3.73 1.96 0.04
2019-03-31 -3.73 1.96 0.04
2018-12-31 -2.67 1.89 0.01
2018-09-30 -2.67 1.89 0.01
2018-06-30 -2.26 0.91 0.04
2018-03-31 -2.26 0.91 0.04
2017-12-31 -0.65 0.00 0.30
2017-09-30 -0.65 0.00 0.30
2017-06-30 0.12 0.00 0.52
2017-03-31 0.12 0.00 0.52
2016-12-31 2.24 0.00 1.65
2016-09-30 2.24 0.00 1.65
2016-06-30 3.75 0.00 4.45
2015-06-30 2.18 0.00 2.58
2014-06-30 0.06 0.00 0.47
2013-06-30 0.98 0.00 1.26
  • Vectus Biosystems has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Vectus Biosystems's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Vectus Biosystems has less than a year of cash runway based on current free cash flow.
  • Vectus Biosystems has less than a year of cash runway if free cash flow continues to reduce at historical rates of -36.9% each year.
X
Financial health checks
We assess Vectus Biosystems's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Vectus Biosystems has a total score of 0/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Vectus Biosystems's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Vectus Biosystems dividends.
If you bought A$2,000 of Vectus Biosystems shares you are expected to receive A$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Vectus Biosystems's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Vectus Biosystems's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:VBS Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 59 Stocks 2.1%
Australia Market Average Dividend Yield Market Cap Weighted Average of 390 Stocks 4%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.5%
Australia Bottom 25% Dividend Yield 25th Percentile 2.4%
Australia Top 25% Dividend Yield 75th Percentile 5.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Vectus Biosystems has not reported any payouts.
  • Unable to verify if Vectus Biosystems's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Vectus Biosystems's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Vectus Biosystems has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Vectus Biosystems's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.5%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Vectus Biosystems afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Vectus Biosystems has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Vectus Biosystems's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Karen Duggan
COMPENSATION A$252,534
CEO Bio

Dr. Karen Annette Duggan serves as the Chief Executive Officer of Vectus Biosystems Limited and has been its Executive Director since September 4, 2006. Dr. Duggan is the Founder of Vectus. She was formally Director of the Hypertension Service - South Western Sydney Area Health Service (SWSAHS), and was Chair of the National Blood Pressure and Vascular Disease Advisory Committee. She remains a member of the Cardiovascular Clinical Expert Reference Group of the NSW Department of Health. In her role as Director of the Hypertension Service SWSAHS, she was responsible for managing a multidisciplinary team (medical, nursing, laboratory and administrative staff), as well as developing and implementing new and innovative strategies in patient care within SWSAHS. Whilst Chair of the NBP&VDAC of the NHFA and a Member of The Executive of the HBPRCA, she set up the Australian Ambulatory Blood Pressure Collaboration, designed a national study and helped co-ordinate data collection and analysis. She has been a Director of Vectus since 2005. Her research has defined the mechanisms by which the body maintains sodium balance in the face of changing oral sodium intake as well as how these mechanisms are deranged in salt-sensitive hypertension. Her research has also defined a major mediator in the development of myocardial and renal fibrosis. She was also a member of the Cardiovascular Health Advisory Committee of the National Heart Foundation of Australia and the Post-Acute Stroke Guidelines Advisory Committee of the Australian Government Department of Health and Aging.

CEO Compensation
  • Karen's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Karen's remuneration is lower than average for companies of similar size in Australia.
Management Team

Karen Duggan

TITLE
CEO & Executive Director
COMPENSATION
A$253K

Graham MacDonald

TITLE
Consultant
COMPENSATION
A$11K

Rob Waring

TITLE
Company Secretary
TENURE
4.3 yrs
Board of Directors Tenure

Average tenure of the Vectus Biosystems board of directors in years:

4.3
Average Tenure
  • The tenure for the Vectus Biosystems board of directors is about average.
Board of Directors

Karen Duggan

TITLE
CEO & Executive Director
COMPENSATION
A$253K
TENURE
13.2 yrs

Maurie Stang

TITLE
Non-Executive Deputy Chairman
COMPENSATION
A$71K

Peter Bush

TITLE
Non Executive Director
COMPENSATION
A$96K
TENURE
4.3 yrs

Susan Pond

TITLE
Independent Non-Executive Director
COMPENSATION
A$45K
TENURE
3.5 yrs

Ron Shnier

TITLE
Independent Non Executive Director
COMPENSATION
A$45K
TENURE
4.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
X
Management checks
We assess Vectus Biosystems's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Vectus Biosystems has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Could The Vectus Biosystems Limited (ASX:VBS) Ownership Structure Tell Us Something Useful?

The big shareholder groups in Vectus Biosystems Limited (ASX:VBS) have power over the company. … Check out our latest analysis for Vectus Biosystems ASX:VBS Ownership Summary, August 29th 2019 What Does The Institutional Ownership Tell Us About Vectus Biosystems? … Private Company Ownership Our data indicates that Private Companies hold 22%, of the company's shares.

Simply Wall St -

What Kind Of Shareholders Own Vectus Biosystems Limited (ASX:VBS)?

Vectus Biosystems is a smaller company with a market capitalization of AU$8.2m, so it may still be flying under the radar of many institutional investors. … Insider Ownership Of Vectus Biosystems The definition of company insiders can be subjective, and does vary between jurisdictions. … Private Company Ownership Our data indicates that Private Companies hold 22%, of the company's shares.

Simply Wall St -

Easy Come, Easy Go: How Vectus Biosystems (ASX:VBS) Shareholders Got Unlucky And Saw 72% Of Their Cash Evaporate

Vectus Biosystems Limited (ASX:VBS) shareholders should be happy to see the share price up 13% in the last month. … Vectus Biosystems didn't have any revenue in the last year, so it's fair to say it doesn't yet have a proven product (or at least not one people are paying for). … But with the share price diving 34% per year, over 3 years, it's probably fair to say that some shareholders no longer believe the company will succeed.

Simply Wall St -

Do Directors Own Vectus Biosystems Limited (ASX:VBS) Shares?

The big shareholder groups in Vectus Biosystems Limited (ASX:VBS) have power over the company. … Generally speaking, as a company grows, institutions will increase their ownership. … Vectus Biosystems is not a large company by global standards.

Simply Wall St -

Why Vectus Biosystems Limited's (ASX:VBS) Ownership Structure Is Important

In this article, I will take a quick look at Vectus Biosystems Limited’s (ASX:VBS) recent ownership structure – an unconventional investing subject, but an important one. … The impact of a company's ownership structure affects both its short- and long-term performance. … Therefore, it is beneficial for us to examine VBS's ownership structure in more detail.

Simply Wall St -

Should You Worry About Vectus Biosystems Limited's (ASX:VBS) CEO Salary Level?

Therefore I will use earnings as a proxy of Duggan's performance in the past year. … In the past year, VBS produced negative earnings of -AU$3.12M. … Usually I'd use market cap and profit as factors determining performance, however, VBS's negative earnings lower the usefulness of my formula.

Simply Wall St -

Who Are The Major Shareholders Of Vectus Biosystems Limited (ASX:VBS)?

Today, I will be analyzing Vectus Biosystems Limited’s (ASX:VBS) recent ownership structure, an important but not-so-popular subject among individual investors. … Insider Ownership I find insiders are another important group of stakeholders, who are directly involved in making key decisions related to the use of capital. … Private Company Ownership Another important group of owners for potential investors in VBS are private companies that hold a stake of 21.42% in VBS.

Simply Wall St -

Does Vectus Biosystems Limited's (ASX:VBS) Latest Financial Perfomance Look Strong?

See our latest analysis for Vectus Biosystems Did VBS's recent earnings growth beat the long-term trend and the industry? … For Vectus Biosystems, its latest trailing-twelve-month earnings is -AU$3.12M, which, relative to last year’s figure, has become less negative. … This means that, Vectus Biosystems has historically performed better than recently, despite the fact that it seems like earnings are now heading back in the right direction again.

Simply Wall St -

Company Info

Description

Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for fibrosis and high blood pressure. Its lead compound is VB0004, which has potent anti-hypertensive properties, as well as anti-fibrotic activity in the heart and kidneys. The company also intends to develop candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis and pulmonary fibrotic diseases. Vectus Biosystems Limited was founded in 2005 and is based in Rosebery, Australia.

Details
Name: Vectus Biosystems Limited
VBS
Exchange: ASX
Founded: 2005
A$13,385,877
23,483,996
Website: http://www.vectusbiosystems.com.au
Address: Vectus Biosystems Limited
3-11 Primrose Avenue,
Rosebery,
New South Wales, 2018,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX VBS Ordinary Shares Australian Securities Exchange AU AUD 23. Feb 2016
CHIA VBS Ordinary Shares Chi-X Australia AU AUD 23. Feb 2016
Number of employees
Current staff
Staff numbers
0
Vectus Biosystems employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/18 10:40
End of day share price update: 2019/11/17 00:00
Last earnings filing: 2019/09/30
Last earnings reported: 2019/06/30
Last annual earnings reported: 2019/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.